Search
MapLight Therapeutics Inc
MPLTAdd to Watchlist
10.760USD
-0.010-0.09%
Close 09-24 16:00（ET）
487.97MMarket Cap
LossP/E TTM
MPLT Analyst Recommendation Trends
In the current month, MPLT has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MPLT average Analyst price target in the last month is 26.538.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
3
3
3
3
3
3
8
8
4
2
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
13
7
5
4
4
4
4
Financial Forecasting
Based on analysts' estimates, MPLT EPS is projected to reach -1.172 in FY2026Q3, following reported EPS of -1.325 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2025Q4
FY2026Q3
FY2026Q4
Forecast
-1.09
-1.31
-0.96
-1.17
-1.10
Actual
-1.34
-1.32
--
--
--
Surprise
-22.54%
-0.80%
--
--
--
FAQs
How have MapLight Therapeutics IncMPLT's recent earnings per share performed?
The market expectation was USD -1.32, while MapLight Therapeutics IncMPLT's earnings per share (EPS) for the previous quarter was USD -1.34. EPS for the next quarter is expected at USD -1.31.
What is the analyst rating for MapLight Therapeutics Inc?
Based on the ratings of MapLight Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.